| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Nivolumab in previously untreated melanoma without BRAF mutation.
|
N Engl J Med
|
2014
|
10.38
|
|
2
|
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
|
J Clin Oncol
|
2013
|
5.36
|
|
3
|
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
|
N Engl J Med
|
2014
|
4.71
|
|
4
|
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
|
J Clin Oncol
|
2009
|
2.63
|
|
5
|
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
|
Breast Cancer Res Treat
|
2008
|
1.82
|
|
6
|
Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population.
|
J Invest Dermatol
|
2006
|
1.80
|
|
7
|
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival.
|
Breast Cancer Res Treat
|
2006
|
1.43
|
|
8
|
Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.
|
Clin Breast Cancer
|
2003
|
1.32
|
|
9
|
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
|
Breast Cancer Res
|
2010
|
1.30
|
|
10
|
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
|
PLoS One
|
2012
|
1.12
|
|
11
|
New challenges in endpoints for drug development in advanced melanoma.
|
Clin Cancer Res
|
2011
|
1.12
|
|
12
|
IFN-α in the treatment of melanoma.
|
J Immunol
|
2012
|
1.12
|
|
13
|
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.
|
Cancer
|
2008
|
1.03
|
|
14
|
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
|
Breast Cancer Res Treat
|
2012
|
1.01
|
|
15
|
Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.
|
Oncology
|
2009
|
1.00
|
|
16
|
Glycogen-rich clear cell carcinoma of the breast.
|
World J Surg Oncol
|
2008
|
0.99
|
|
17
|
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
|
Breast Cancer Res Treat
|
2006
|
0.97
|
|
18
|
Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
|
Breast Cancer Res Treat
|
2005
|
0.95
|
|
19
|
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".
|
J Transl Med
|
2013
|
0.95
|
|
20
|
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.
|
Breast Cancer Res Treat
|
2011
|
0.94
|
|
21
|
Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients.
|
Breast Cancer Res Treat
|
2007
|
0.94
|
|
22
|
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.
|
BMC Cancer
|
2014
|
0.93
|
|
23
|
Replication and predictive value of SNPs associated with melanoma and pigmentation traits in a Southern European case-control study.
|
PLoS One
|
2013
|
0.92
|
|
24
|
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
|
Clin Breast Cancer
|
2012
|
0.91
|
|
25
|
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
|
Semin Immunopathol
|
2011
|
0.90
|
|
26
|
Risk associations of melanoma in a Southern European population: results of a case/control study.
|
Cancer Causes Control
|
2008
|
0.90
|
|
27
|
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
|
BMC Cancer
|
2013
|
0.90
|
|
28
|
The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
|
Breast Cancer Res
|
2012
|
0.89
|
|
29
|
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
|
J Transl Med
|
2012
|
0.89
|
|
30
|
Nonmelanoma skin tumors involving the craniofacial region: our 22 years of experience.
|
J Craniofac Surg
|
2007
|
0.89
|
|
31
|
Metastatic melanoma in the gallbladder: report of a case.
|
Surg Today
|
2003
|
0.88
|
|
32
|
Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study.
|
Eur J Epidemiol
|
2012
|
0.87
|
|
33
|
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".
|
J Transl Med
|
2012
|
0.87
|
|
34
|
Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
|
Support Care Cancer
|
2014
|
0.85
|
|
35
|
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
|
Breast Cancer Res Treat
|
2005
|
0.85
|
|
36
|
Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance.
|
Clin Chem Lab Med
|
2009
|
0.85
|
|
37
|
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.
|
Breast Cancer Res
|
2009
|
0.85
|
|
38
|
Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
|
PLoS One
|
2013
|
0.84
|
|
39
|
Severe thrombocytopenia related to trastuzumab infusion.
|
Med Sci Monit
|
2011
|
0.84
|
|
40
|
Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group.
|
Anticancer Res
|
2008
|
0.84
|
|
41
|
Insulin resistance in relation to melanoma risk.
|
Melanoma Res
|
2011
|
0.83
|
|
42
|
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study.
|
Anticancer Res
|
2005
|
0.83
|
|
43
|
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
|
Melanoma Res
|
2004
|
0.82
|
|
44
|
A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.
|
PLoS One
|
2012
|
0.82
|
|
45
|
Methods of detection of circulating melanoma cells: a comparative overview.
|
Cancer Treat Rev
|
2010
|
0.82
|
|
46
|
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
|
Cancer Invest
|
2004
|
0.81
|
|
47
|
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
|
Oncology
|
2008
|
0.81
|
|
48
|
A study of a single variant allele (rs1426654) of the pigmentation-related gene SLC24A5 in Greek subjects.
|
Exp Dermatol
|
2008
|
0.81
|
|
49
|
Diagnosis and treatment of intracystic breast carcinomas.
|
Am Surg
|
2002
|
0.81
|
|
50
|
Treatment algorithms in stage IV melanoma.
|
Am J Ther
|
2015
|
0.80
|
|
51
|
Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
|
Anticancer Res
|
2007
|
0.80
|
|
52
|
Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes.
|
Anticancer Res
|
2009
|
0.79
|
|
53
|
Evaluation of self-assessed melanoma growth rate in a Mediterranean patient population.
|
Melanoma Res
|
2011
|
0.78
|
|
54
|
Advances in adjuvant therapy: potential for prognostic and predictive biomarkers.
|
Methods Mol Biol
|
2014
|
0.78
|
|
55
|
Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
|
Anticancer Res
|
2003
|
0.78
|
|
56
|
Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer.
|
Med Oncol
|
2006
|
0.77
|
|
57
|
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
|
J Cancer Res Clin Oncol
|
2012
|
0.77
|
|
58
|
Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin.
|
Anticancer Res
|
2006
|
0.77
|
|
59
|
Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study.
|
Med Oncol
|
2007
|
0.76
|
|
60
|
Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel.
|
Anticancer Res
|
2009
|
0.76
|
|
61
|
Expression of p27KIP1, p21WAF1 and p53 does not correlate with prognosis in node-negative invasive ductal carcinoma of the breast.
|
Anticancer Res
|
2006
|
0.76
|
|
62
|
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group.
|
Lung Cancer
|
2003
|
0.76
|
|
63
|
Mucosa-associated lymphoid tissue thyroid lymphoma: a rare and not aggressive tumour.
|
Eur J Surg
|
2002
|
0.75
|
|
64
|
Encephalitis in a Patient With Melanoma Treated With Immune Checkpoint Inhibitors: Case Presentation and Review of the Literature.
|
J Immunother
|
2020
|
0.75
|
|
65
|
Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.
|
J Immunother
|
2017
|
0.75
|
|
66
|
Weekly Gemcitabine plus Fluorouracil-Folinic Acid Given Weekly for Two Days in Patients with Advanced Pancreatic Cancer : A Phase II Study.
|
Clin Drug Investig
|
2004
|
0.75
|
|
67
|
Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.
|
Oncol Rep
|
2010
|
0.75
|
|
68
|
The role of adiponectin as a compensatory mediator for the primary secretory defect in latent autoimmune diabetes in adults.
|
Clin Ther
|
2013
|
0.75
|
|
69
|
Advances and trends in dermato-oncology.
|
Expert Rev Anticancer Ther
|
2010
|
0.75
|
|
70
|
Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events.
|
Melanoma Res
|
2017
|
0.75
|